|
|
 Previous Article | Table of Contents | Next Article 
A variant form of hairy cell leukemia resistant to alpha-interferon:
clinical and phenotypic characteristics of 17 patients
L Sainati, E Matutes, S Mulligan, MP de Oliveira, S Rani, IA Lampert and D Catovsky
Academic Department of Haematology and Cytogenetics, Royal Marsden
Hospital, London, UK.
We describe the clinical and laboratory features of 17 adult patients with
a variant form of hairy cell leukemia (HCL-V) studied over the last 7
years. The main findings were: splenomegaly, moderate anemia,
thrombocytopenia, and a raised white blood cell count (median 116 x
10(9)/L; range 15 to 482). The circulating lymphoid cells had abundant
villous cytoplasm and a round, occasionally bilobed nucleus, with a
prominent nucleolus. Monocytopenia, a feature of typical HCL, was not seen;
neither was tartrate-resistant acid phosphatase demonstrated in eight cases
tested. HCL-V cells had a mature B-cell phenotype: CD19+, CD20+, CD22+,
FMC7+, CD11c+, CD10-, CD5-, with light chain isotope restriction in 15
cases. In contrast to typical hairy cells, HCL-V cells were negative with
the monoclonal antibodies anti-HC2 and anti- TAC (CD25). Immunoglobulin
(Ig) was not detected in two cases and IgG was expressed in the cell
membrane of 73% of cases. Bone marrow histology was different from HCL,
showing interstitial infiltration by cells clumped together and a moderate
amount of reticulin, but the spleen showed the typical red pulp expansion
of HCL. HCL-V patients did not respond to splenectomy (5 of 7) or
alpha-interferon (7 of 7); 2 of 3 patients had a partial response to
2'deoxycoformycin. The clinical course was benign with 15 patients alive
with a median survival greater than 4 years. We confirm that HCL-V is a
distinct clinico-pathologic entity with intermediate features between HCL
and B-prolymphocytic leukemia.
Volume 76,
Issue 1,
pp. 157-162,
07/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. O. Wanko and C. de Castro
Hairy Cell Leukemia: An Elusive but Treatable Disease
Oncologist,
July 1, 2006;
11(7):
780 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Basso, A. Liso, E. Tiacci, R. Benedetti, A. Pulsoni, R. Foa, F. Di Raimondo, A. Ambrosetti, A. Califano, U. Klein, et al.
Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors
J. Exp. Med.,
January 5, 2004;
199(1):
59 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Rohr, S.-F. H. Schmitz, A. Tichelli, U. Hess, D. Piguet, M. Wernli, N. Frickhofen, G. Konwalinka, G. Zulian, M. Ghielmini, et al.
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Ann. Onc.,
October 1, 2002;
13(10):
1641 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
